Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation.
- Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation.
- The drug formulation was designed to enhance brain distribution of its lead drug candidate, PRV-002, to treat concussion (mild traumatic brain injury).
- The combined nature of our new formulation and novel nasal device will maximize the exposure of the traumatized brain to our drug following concussion and give the best chance for effective treatment, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
- The novel nanoparticle drug formulation will improve safety by reducing exposure to areas of the body other than the intended treatment area, the brain,
The drug, a novel neurosteroid being developed to treat concussion, has been formulated into a nano-particle powder.